Patent · US Active

Smallpox monoclonal antibody

US7811568B2 · kind B2 · utility

1Cited by
2References
11Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 22, 2007
Grant dateOct 12, 2010
Priority date
Expiry dateJun 11, 2028

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/76
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Humanized monoclonal antibodies against the vaccinia virus B5R surface antigen. The antibodies are effective in treating smallpox infection. Also disclosed are nucleic acids that encode the heavy and light chains of such antibodies and cells that express them.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.